In recent years, the advent of prostate-specific membrane antigen (PSMA) positron emission tomography (PET) has revolutionized the diagnostic and staging approach in prostate cancer [5], providing enhanced sensitivity for the detection of localized and metastatic disease. This evidence concerns the gene FOLH1 and Familial prostate cancer.